Timber Pharmaceuticals

Biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases.

[Timber Pharmaceuticals @TimberPharma]

Today we entered into a definitive agreement to be acquired by LEO Pharma @LEOHealthySkin, a wholly-owned subsidiary of LEO Pharma A/S. The transaction is expected to close in the fourth quarter of 2023 subject to closing conditions. See our press release: https://t.co/MsJMX46TGk

[Timber Pharmaceuticals @TimberPharma]

Today we shared interim pharmacokinetic analyses from the Phase 3 ASCEND study, our pivotal clinical trial for moderate to severe X-linked (RXLI) or lamellar #ichthyosis (ARCI). We plan to present the data at #SPD2023 in July. Find details: https://t.co/MsJMX46TGk

[Timber Pharmaceuticals @TimberPharma]

Peyton lives with X-linked #ichthyosis, characterized by dry, scaly patches of skin that cover the body. “When I’m not itching, I just feel different. I feel better, because I’m not constantly scratching.” Read more from @FIRST_Skin: https://t.co/VRMMT0tDNi

[Timber Pharmaceuticals @TimberPharma]

We’re grateful for the support of @YaleMed, which has been an integral part of our congenital #ichthyosis development program as the only U.S. site involved in all 3 of our clinical trials. Dr. Chris Bunick talks more about the study in @DermTimes: https://t.co/PAcpVCsjYi

[Timber Pharmaceuticals @TimberPharma]

As we recognize the end of #IchthyosisAwarenessMonth, we encourage you to visit @FIRST_Skin to learn more about congenital #ichthyosis and its impact on patients and families: https://t.co/cFp3ZQQZa1

[Timber Pharmaceuticals @TimberPharma]

After developing itchy, painful scales on his skin, Aditya was diagnosed with congenital #ichthyosis (CI) at seven years old. Now, he’s sharing his story to build awareness of this rare genetic skin condition and help others feel less alone. Read more: https://t.co/iTJsp3rWDI

[Timber Pharmaceuticals @TimberPharma]

Learn more about the ASCEND study, a randomized controlled pivotal Phase 3 clinical trial in patients with autosomal recessive congenital ichthyosis lamellar ichthyosis (ARCI-LI) or X-linked recessive #ichthyosis (XRI). Learn more at https://t.co/46JkhuQ47O

[Timber Pharmaceuticals @TimberPharma]

May 20 marks #ClinicalTrialsDay. As we continue to advance our pivotal Phase 3 ASCEND study for congenital #ichthyosis, we thank the site investigators, research staff, patients, caregivers and families who have helped us move this important research effort forward.

[Timber Pharmaceuticals @TimberPharma]

Earlier this year, @DermTimes included details of a sub-analysis of the Phase 2B CONTROL study that was recently published online in Clinical and Experimental Dermatology. Read now: https://t.co/UMFYSl93Fn

[Timber Pharmaceuticals @TimberPharma]

Peyton Fleagle was just a toddler when his parents first noticed itchy scales on his skin. Eventually the scales covered 95% of Peyton's body. @Medical_xpress shares more about our work on behalf of Peyton & all those living with congenital #ichthyosis: https://t.co/ZfsZS0rIBa

[Timber Pharmaceuticals @TimberPharma]

Thanks to Dr. Joyce Teng of Stanford University School of Medicine, for contributing her perspectives to a @Healio article covering an analysis of our Phase IIb CONTROL study for congenital #ichthyosis. Read now: https://t.co/8w06ShxzIj

[Timber Pharmaceuticals @TimberPharma]

May is #Ichthyosis Awareness Month, an opportunity to join with patients & families around the world to raise awareness about the challenges & hopes of the ichthyosis community. Learn how you can get involved: https://t.co/lPaRVDwtBb #IAM23 @FIRST_Skin

[Timber Pharmaceuticals @TimberPharma]

Today we announced the online publication of a sub-analysis of the Phase 2B CONTROL study in Clinical and Experimental Dermatology (CED), the educational journal of the British Association of Dermatologists (@HealthySkin4All). See our press release: https://t.co/MsJMX46TGk

[Timber Pharmaceuticals @TimberPharma]

We’re grateful to work with patient advocates who are passionate about sharing their stories with their communities to raise awareness of congenital #ichthyosis & opportunities to participate in clinical research. The Fleagle family shares their story: https://t.co/dW5hZMOnVU

[Timber Pharmaceuticals @TimberPharma]

The @AADskin Annual Meeting begins today! #AAD2023 will discuss some of the most important topics and latest updates in #dermatology and provide the opportunity to connect with more than 8k members of the clinical and research community.

View here: https://t.co/BYhyQ6V04u

[Timber Pharmaceuticals @TimberPharma]

#ICYMI Last month, we received orphan drug designation for our lead candidate in development for the treatment of X-linked recessive #ichthyosis (XLRI) from the European Commission. Learn more: https://t.co/MsJMX46TGk

[Timber Pharmaceuticals @TimberPharma]

In an interview with @AuthorityMag, Christina and Peyton share their experiences with X-linked #ichthyosis in an effort to build awareness of this rare genetic skin disorder: https://t.co/uERZ1FAIm7

[Timber Pharmaceuticals @TimberPharma]

Aditya was recently interviewed as part of @AuthorityMag’s #Unstoppable series, where he shared his story & talked about his work as a patient advocate and desire to help others living with congenital #ichthyosis. Read now: https://t.co/5GmBAmVPQu

[Timber Pharmaceuticals @TimberPharma]

Thank you to the Fleagle family & Dr. Christopher Bunick of @yalederm for creating greater awareness of congenital #ichthyosis and the work we are doing, together, to help patients in need. Read now: https://t.co/j0QA7jXwxg

[Timber Pharmaceuticals @TimberPharma]

Today we recognize #RareDiseaseDay and show our support for the 300+ million individuals impacted by #rarediseases worldwide, including #ichthyosis.

Join us today in celebrating #RDD2023 with @First_Skin: https://t.co/KRDxAefeMn